Q2 outlook disappoints market, but Elekta is only for the patient ones
28/08/25 -"While Q1 profitability exceeded expectations, investors were disappointed by the weak Q2 outlook due to expected underperformance in the US and China, alongside FX headwinds and tariff impacts. ..."
Pages
65
Language
English
Published on
28/08/25
You may also be interested by these reports :
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...
29/08/25
Despite being a dominant player in the ophthalmology space, Alcon has been reeling under the pressure of slower than expected market growth this ...